271 related articles for article (PubMed ID: 23240670)
1. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
Gurung A; Hung T; Morin J; Gilks CB
Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
[TBL] [Abstract][Full Text] [Related]
2. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
3. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
4. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
Canet B; Pons C; Espinosa I; Prat J
Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
[TBL] [Abstract][Full Text] [Related]
5. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
6. A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection.
Zhou F; Cao X; Liu M; Wang Y; Tao G
Clin Lab; 2011; 57(5-6):421-4. PubMed ID: 21755835
[TBL] [Abstract][Full Text] [Related]
7. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas.
Sarrió D; Moreno-Bueno G; Sánchez-Estévez C; Bañón-Rodríguez I; Hernández-Cortés G; Hardisson D; Palacios J
Hum Pathol; 2006 Aug; 37(8):1042-9. PubMed ID: 16867867
[TBL] [Abstract][Full Text] [Related]
8. My approach to and thoughts on the typing of ovarian carcinomas.
McCluggage WG
J Clin Pathol; 2008 Feb; 61(2):152-63. PubMed ID: 17704261
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer.
Katso RM; Manek S; Biddolph S; Whittaker R; Charnock MF; Wells M; Ganesan TS
Cancer Res; 1999 May; 59(10):2265-70. PubMed ID: 10344726
[TBL] [Abstract][Full Text] [Related]
11. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer is a heterogeneous disease.
Wang V; Li C; Lin M; Welch W; Bell D; Wong YF; Berkowitz R; Mok SC; Bandera CA
Cancer Genet Cytogenet; 2005 Sep; 161(2):170-3. PubMed ID: 16102589
[TBL] [Abstract][Full Text] [Related]
13. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
15. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma.
Lin CK; Chao TK; Lai HC; Lee HS
Am J Clin Pathol; 2012 Jun; 137(6):971-7. PubMed ID: 22586057
[TBL] [Abstract][Full Text] [Related]
16. Prognostic results of cisplatin IP and carboplatin IV with G-CSF in patients with ovarian cancer.
Adachi S; Itani Y; Ito K; Noda T; Shintani M; Saito K; Furukawa N; Tomii Y
Oncol Rep; 2001; 8(1):27-31. PubMed ID: 11115564
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
[TBL] [Abstract][Full Text] [Related]
18. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
19. Interphase fluorescence in situ hybridization studies of ovarian adenocarcinomas using the midisatellite probe.
Kalir T; Eisberg A; Dottino P; Cohen C
Gynecol Oncol; 1999 Feb; 72(2):208-14. PubMed ID: 10021303
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer update: lessons from morphology, molecules, and mice.
Cho KR
Arch Pathol Lab Med; 2009 Nov; 133(11):1775-81. PubMed ID: 19886711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
